EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Nitrofurantoin treatment and prophylaxis for recurrent urinary tract infections in women: First-line for a reason

Alec Szlachta-McGinn iD, A Lenore Ackerman iD

PLOS Pathogens · 13.08.2026 · 22 (8) · e1014516

DOI: 10.1371/journal.ppat.1014516 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PLOS Pathogens, online erschienen am 13.08.2026. Verfasst von Alec Szlachta-McGinn und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Division of Urogynecology and Reconstructive Pelvic Surgery, Washington University in St. Louis, St. Louis, …. Hauptthemen laut MEDLINE: Nitrofurantoin, Urinary Tract Infections, Anti-Infective Agents, Urinary, Anti-Bacterial Agents. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCCIH NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nitrofurantoin is considered a first-line antimicrobial agent by the AUA/CUA/SUFU Guideline and Infectious Disease Society of America (IDSA) Guideline for the treatment of acute uncomplicated simple cystitis in women. Nitrofurantoin has good oral bioavailability, high concentration in urine, and low serum and tissue concentrations. These characteristics result in minimal collateral damage to the microbial composition of other niches within the human body, such as the gut, that are essential in maintaining homeostasis. In addition, resistance to nitrofurantoin is uncommon owing to its interference with multiple bacterial cellular functions critical to survival. Large systematic reviews and meta-analyses have demonstrated that nitrofurantoin is noninferior to other commonly prescribed antibiotics for treatment of urinary tract infection (UTI). Recent data from a randomized controlled trial suggest that a 5-day course of nitrofurantoin may be more effective than a single dose of fosfomycin in the treatment of UTI. Therefore, nitrofurantoin is an ideal first-line agent in the management of UTI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitrofurantoinUrinary Tract InfectionsAnti-Infective Agents, UrinaryAnti-Bacterial AgentsHumansFemaleCystitis

Substanzen

NitrofurantoinAnti-Infective Agents, UrinaryAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Division of Urogynecology and Reconstructive Pelvic Surgery, Washington University in St. Louis, St. Louis, Missouri, United States of America.
  • Department of Urology, Division of Urogynecology and Reconstructive Pelvic Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.

ORCID-Profile: Alec Szlachta-McGinn, A Lenore Ackerman

Förderung

  • NIDDK NIH HHS
  • NCCIH NIH HHS
  • National Institutes of Health
  • DOW

Zitieren

APA

Szlachta-McGinn, A., & Ackerman, A. L. (2026). Nitrofurantoin treatment and prophylaxis for recurrent urinary tract infections in women: First-line for a reason. PLOS Pathogens, 22(8), e1014516. https://doi.org/10.1371/journal.ppat.1014516

Vancouver

Szlachta-McGinn A, Ackerman AL. Nitrofurantoin treatment and prophylaxis for recurrent urinary tract infections in women: First-line for a reason. PLOS Pathogens. 2026;22(8):e1014516. doi:10.1371/journal.ppat.1014516

BibTeX
@article{SzlachtaMcGinn2026,
  author = {Szlachta-McGinn, Alec and Ackerman, A Lenore},
  title = {Nitrofurantoin treatment and prophylaxis for recurrent urinary tract infections in women: First-line for a reason},
  journal = {PLOS Pathogens},
  year = {2026},
  volume = {22},
  number = {8},
  pages = {e1014516},
  doi = {10.1371/journal.ppat.1014516}
}
Kostenlos starten →